8-K: Yield10 Bioscience Prioritizes Omega-3 Camelina Program, Awaits Nasdaq Listing Decision

Yield10 Bioscience is prioritizing its Omega-3 Camelina program for commercialization in 2024 and is awaiting a decision regarding its Nasdaq listing.

Summary

• Yield10 Bioscience is focusing on accelerating its Omega-3 Camelina program towards commercialization in 2024.
• The company has completed contra-season production of Omega-3 EPA8 Camelina seed in Chile.
• Yield10 aims to secure a global commercial license from Rothamsted and collaborate with BioMar to produce omega-3 oils for aquafeed.
• The company is scaling up seed production of EPA8 Camelina and working on regulatory approvals in the US.
• Yield10 is also transferring the EPA trait into herbicide-tolerant Camelina to improve agronomics and yield.
• The company is awaiting a decision from the Nasdaq Hearings Panel regarding its listing status after an appeal related to minimum stockholders' equity.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there is positive progress in the Omega-3 Camelina program, the uncertainty surrounding the Nasdaq listing and the need for sufficient financial resources temper the overall outlook.

Positives

• The strategic decision to prioritize the Omega-3 Camelina program demonstrates a clear focus on a key product.
• Completion of contra-season production in Chile provides a seed inventory for future use.
• The potential collaboration with BioMar could provide a strong commercial pathway for omega-3 oils in aquafeed.
• The company is actively working on regulatory approvals, which is crucial for commercialization.
• Transferring the EPA trait into herbicide-tolerant Camelina could improve yields and reduce costs.

Negatives

• The company's Nasdaq listing is under review due to not meeting minimum stockholders' equity requirements.
• The company's plans are subject to the availability of sufficient financial resources.
• The company is still awaiting responses from USDA-APHIS on its Regulatory Status Review applications.

Risks

• The company's ability to secure adequate funding in the near term is a significant risk to its operations and commercialization plans.
• There is no guarantee that the company will be granted a further extension to meet Nasdaq listing requirements.
• The regulatory approval process can be lengthy and uncertain.
• The company's commercial success depends on the successful scale-up of seed production and the formation of partnerships.

Future Outlook

Yield10 plans to commercialize omega-3 Camelina by securing a global commercial license, engaging BioMar, and continuing seed scale-up and regulatory programs, subject to the availability of sufficient financial resources.

Management Comments

• Oliver Peoples, Ph.D., President and CEO, stated that in 2023, they achieved significant milestones in their omega-3 Camelina program.
• Oliver Peoples also mentioned that they signed an LOI with BioMar who recently reiterated their commitment to jointly working with them.

Industry Context

The announcement highlights the growing demand for sustainable sources of omega-3 oils, particularly for aquafeed, as traditional sources from ocean-caught fish face supply constraints and price volatility. This positions Yield10's Camelina-based omega-3 production as a potential solution to meet this demand.

Comparison to Industry Standards

• The document mentions that the industry benchmark for omega-3 oil is produced from anchovy harvest.
• Yield10's approach of producing omega-3 fatty acids in Camelina is aimed at providing a cost-effective and scalable alternative to traditional sources.
• The company is targeting the aquafeed market, which is a significant consumer of omega-3 oils, similar to other companies in the aquaculture feed industry.
• The company's collaboration with BioMar, a global aquafeed producer, is a strategic move to gain market access and establish a reliable supply chain.

Stakeholder Impact

• Shareholders are impacted by the uncertainty surrounding the Nasdaq listing and the need for additional funding.
• Employees are impacted by the company's strategic shift and the need to execute on the Omega-3 Camelina program.
• Customers in the aquafeed industry could benefit from a new, sustainable source of omega-3 oils.
• Suppliers of Camelina seed and processing equipment could see increased demand.
• Creditors are impacted by the company's financial situation and the need for additional funding.

Next Steps

• Yield10 will continue to execute seed scale-up of EPA8 Camelina.
• The company will continue to work on regulatory approvals for its Omega-3 Camelina.
• Yield10 will finalize the global exclusive license with Rothamsted.
• The company will engage with BioMar to support a collaborative program.
• Yield10 is awaiting the determination of the Nasdaq Hearings Panel regarding its listing status.

Key Dates

Keywords

Omega-3, Camelina, Aquafeed, EPA, DHA, Rothamsted, BioMar, Nasdaq, Regulatory Approvals, Seed Production